Litcius/Paper detail

Metformin attenuates white matter injury and cognitive impairment induced by chronic cerebral hypoperfusion

Yixi He, Zhenghao Li, Xiaoyu Shi, Jing Ding, Xin Wang

2023Journal of Cerebral Blood Flow & Metabolism10 citationsDOIOpen Access PDF

Abstract

Vascular cognitive impairment and dementia (VCID) is a series of cognitive dysfunction associated with cerebrovascular diseases and currently lacks effective treatments. The white matter, which is essential for neuronal information processing and integration, is nourished by a network of capillaries and is vulnerable to chronic hypoperfusion. Here, we show that metformin, a widely used drug for the treatment of type 2 diabetes, alleviates the white matter damage and improves cognitive impairment in a mouse model of VCID established by bilateral carotid artery stenosis (BCAS)-induced chronic hypoperfusion. Mechanistically, metformin restores the dysfunctions of oligodendrocyte precursor cells (OPCs) under hypoxia. Metformin up-regulates prolyl hydroxylases 2 via activating the AMP-activated protein kinase pathway, leading to hypoxia-inducible factor-1α (HIF-1α) degradation in OPCs. These findings suggest that metformin may have a promising therapeutic role in alleviating cognitive abnormalities by ameliorating white matter damage of VCID.

Topics & Concepts

MetforminWhite matterMedicineHypoxia (environmental)Cerebral hypoperfusionNeuroprotectionVascular dementiaDementiaCardiologyCognitive declineInternal medicineNeurosciencePerfusionDiabetes mellitusEndocrinologyPsychologyMagnetic resonance imagingRadiologyOxygenOrganic chemistryChemistryDiseaseNeurological Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration MechanismsNeurological Disorders and Treatments
Metformin attenuates white matter injury and cognitive impairment induced by chronic cerebral hypoperfusion | Litcius